Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;31(2):224-230.
doi: 10.1111/hae.15131. Epub 2025 Feb 12.

In vitro combined haemostatic efficacy of emicizumab and extended half-life factor VIII compounds

Laurie Josset  1 , Hamdi Rezigue  1   2 , Christophe Nougier  1   2 , Alexandre Leuci  1 , Stéphanie Désage  3 , Anne Lienhart  3 , Yesim Dargaud  1   3
Affiliations

In vitro combined haemostatic efficacy of emicizumab and extended half-life factor VIII compounds

Laurie Josset et al. Haemophilia. 2025 Mar.

Abstract

Introduction: Early prophylaxis is the gold standard of care for severe haemophilia. The development of subcutaneous Factor VIII (FVIII) mimetics, such as emicizumab, has significantly reduced the disease burden and improved protection against bleeding episodes. Despite its benefits, emicizumab does not fully normalize haemostasis, requiring additional FVIII treatment for surgical procedures and management of breakthrough bleeding. In these cases, extended or ultra-extended half-life FVIII products are most commonly used. However, laboratory monitoring of these combinations can be challenging.

Aim: This study investigates the in vitro combined haemostatic activity of emicizumab with efmoroctocog alfa and efanesoctocog alfa using a thrombin generation assay (TGA).

Results and conclusion: TGA can be used to monitor combined treatment with emicizumab and either efmoroctocog alfa or efanesoctocog alfa, which is not possible with currently available FVIII reagents for the latter. As expected, there is no synergistic effect between the mimetic and FVIII at therapeutical doses. Both efmoroctocog alfa and efanesoctocog alfa show similar in vitro procoagulant activity in terms of thrombin generation.

Keywords: efanesoctocog alfa; efmoroctocog alfa; emicizumab; haemophilia A; thrombin generation assay.

PubMed Disclaimer

References

REFERENCES

    1. Carcao M, Zunino L, Young NL, et al. Measuring the impact of changing from standard half‐life (SHL) to extended half‐life (EHL) FVIII prophylaxis on health‐related quality of life (HRQoL) in boys with moderate/severe haemophilia A: lessons learned with the CHO‐KLAT tool. Haemophilia. 2020;26:73‐78.
    1. Frampton JE. Efmoroctocog alfa: a review in haemophilia A. Drugs. 2021;81:2035‐2046.
    1. Benson G, Morton T, Thomas H, Lee XY. Long‐term outcomes of previously treated adult and adolescent patients with severe hemophilia A receiving prophylaxis with extended half‐life FVIII treatments: an economic analysis from a United Kingdom perspective. Clinicoecon Outcomes Res. 2021;13:39‐51.
    1. Young G, Auerswald G, Jimenez‐Yuste V, et al. When should prophylaxis therapy in inhibitor patients be considered? Haemophilia. 2011;17:e849‐857.
    1. Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130:2463‐2468.

MeSH terms